X

Trial Profile

A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Cisplatin; Ifosfamide; Paclitaxel
Indications Penile cancer
Focus Therapeutic Use
Acronyms PENILANE

Most Recent Events

24 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
10 Feb 2015 Planned End Date changed from 1 May 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
10 Feb 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com